€26.90
0.30% today
L&S, Jul 02, 08:53 pm CET
ISIN
US4579852082
Symbol
IART

Integra LifeSciences Holdings Corporation Target price 2024 - Analyst rating & recommendation

Integra LifeSciences Holdings Corporation Classifications & Recommendation:

Buy
21%
Hold
57%
Sell
21%

Integra LifeSciences Holdings Corporation Target price

Target price $34.20
Course $28.97
Price potential
Number of estimates 10
10 Analysts have issued a price target Integra LifeSciences Holdings Corporation 2025 . The average Integra LifeSciences Holdings Corporation target price is $34.20. This is higher than the current share price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 3 Analysts recommend Integra LifeSciences Holdings Corporation to buy, 8 to hold and 3 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst estimates: Analysts believe that the Integra LifeSciences Holdings Corporation share has an average upside potential 2025 of . Most analysts recommend the Integra LifeSciences Holdings Corporation share at Hold.

Sales and margin forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Forecast
Turnover Billion $ 1.54 1.67
1.03% 8.34%
EBITDA margin 19.30% 22.15%
13.78% 14.74%
Net margin 4.29% 5.30%
60.70% 23.51%

12 Analysts have issued a sales forecast Integra LifeSciences Holdings Corporation 2024 . The average Integra LifeSciences Holdings Corporation sales estimate is

$1.7b
Unlock
. This is
9.19% higher
Unlock
than the turnover of the last 12 months(TTM). The highest sales forecast is
$1.7b 9.82%
Unlock
, the lowest is
$1.6b 5.32%
Unlock
.

This results in the following potential growth figures:

Sales forecast

2023 $1.5b 1.03%
2024
$1.7b 8.34%
Unlock
2025
$1.8b 5.72%
Unlock
2026
$1.9b 5.00%
Unlock

8 Analysts have issued an Integra LifeSciences Holdings Corporation EBITDA forecast 2024. The average Integra LifeSciences Holdings Corporation EBITDA estimate is

$370m
Unlock
. This is
43.92% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$381m 48.20%
Unlock
, the lowest is
$351m 36.53%
Unlock
.

This results in the following potential growth figures and future EBITDA margins:

EBITDA forecast

2023 $298m 14.67%
2024
$370m 24.34%
Unlock
2025
$402m 8.55%
Unlock
2026
$431m 7.28%
Unlock

EBITDA margin

2023 19.30% 13.78%
2024
22.15% 14.74%
Unlock
2025
22.75% 2.71%
Unlock
2026
23.24% 2.15%
Unlock

3 Integra LifeSciences Holdings Corporation Analysts have issued a net profit forecast 2024. The average Integra LifeSciences Holdings Corporation net profit estimate is

$88.5m
Unlock
. This is
120.26% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$118m 194.13%
Unlock
, the lowest is
$56.7m 41.18%
Unlock
.

This results in the following potential growth figures and future net margins:

Net profit forecast

2023 $66.2m 61.11%
2024
$88.5m 33.73%
Unlock
2025
$153m 73.00%
Unlock
2026
$163m 6.51%
Unlock

Net margin

2023 4.29% 60.70%
2024
5.30% 23.51%
Unlock
2025
8.67% 63.58%
Unlock
2026
8.79% 1.38%
Unlock

Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Forecast
Earnings per share $ 0.84 1.12
61.11% 33.33%
P/E ratio 25.79
EV/Sales 2.19

3 Analysts have issued a Integra LifeSciences Holdings Corporation forecast for earnings per share. The average Integra LifeSciences Holdings Corporation <a href=/blog/eps>EPS is

$1.12
Unlock
. This is
119.61% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is
$1.50 194.12%
Unlock
, the lowest is
$0.72 41.18%
Unlock
.

This results in the following potential growth figures and future valuations:

Earnings per share

2023 $0.84 61.11%
2024
$1.12 33.33%
Unlock
2025
$1.94 73.21%
Unlock
2026
$2.07 6.70%
Unlock

P/E ratio

Current 57.15 159.65%
2024
25.79 54.87%
Unlock
2025
14.91 42.19%
Unlock
2026
14.00 6.10%
Unlock

Based on analysts' sales estimates for 2024, the Integra LifeSciences Holdings Corporation share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of

and an <a href=/blog/kurs-umsatz-verhaeltnis-kuv-einfach-erklaert>P/S ratio of .

This results in the following potential growth figures and future valuations:

EV/Sales

Current 2.39 20.07%
2024
2.19 8.26%
Unlock
2025
2.07 5.41%
Unlock
2026
1.98 4.76%
Unlock

P/S ratio

Current 1.49 30.81%
2024
1.37 8.42%
Unlock
2025
1.29 5.41%
Unlock
2026
1.23 4.76%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today